An Open-label, Single-arm, Multi-center, Phase II Clinical Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
Latest Information Update: 06 Dec 2023
At a glance
- Drugs MRG 002 (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- Sponsors Miracogen
- 10 Aug 2021 Status changed from not yet recruiting to recruiting.
- 09 Apr 2021 New trial record